echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Junzheng Group invested 1.12 billion yuan in Da'an pharmaceutical to enter the field of blood products!

    Junzheng Group invested 1.12 billion yuan in Da'an pharmaceutical to enter the field of blood products!

    • Last Update: 2020-02-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Junzheng group announced today that Shengtai Information Technology Development Co., Ltd., a wholly-owned holding company of Lhasa Economic and Technological Development Zone (hereinafter referred to as "Lhasa Shengtai"), intends to subscribe for an additional capital contribution of 357.1429 million yuan from Hebei Da'an Pharmaceutical Co., Ltd (hereinafter referred to as "Da'an pharmaceutical"), with a corresponding investment amount of 112, 1.9987 million yuan, accounting for 31.17% of the registered capital of Da'an pharmaceutical after this capital increase and share expansion The evaluation / valuation of Da'an pharmaceutical has not been determined yet The tentative valuation of Da'an pharmaceutical in this transaction is RMB 2.1 billion, which corresponds to about 35.29 times of the net profit of Da'an pharmaceutical in 2018 The valuation of Da'an pharmaceutical after the completion of the previous capital increase is about RMB 1.939 billion, which may pose a higher valuation risk Gongjunzheng group's main business is the production and sale of chemical products Daan pharmaceutical is mainly engaged in the production and sale of blood products There are great differences between the two industries The capital increase of Daan Pharmaceutical by Junzheng group this time belongs to cross industry investment, which may have certain investment risks Da'an pharmaceutical's net profit in the first three quarters of 2019 was 13.9118 million yuan, a large decline compared with 59.4993 million yuan in the whole year of 2018 There is a risk that Da'an pharmaceutical's operating performance will decline significantly in the whole year After the capital increase, the equity structure of Da'an in Hebei will be as follows: Mengmeng
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.